PL2897978T3 - Sposoby identyfikacji przeciwciał o obniżonej immunogenności - Google Patents

Sposoby identyfikacji przeciwciał o obniżonej immunogenności

Info

Publication number
PL2897978T3
PL2897978T3 PL13773474T PL13773474T PL2897978T3 PL 2897978 T3 PL2897978 T3 PL 2897978T3 PL 13773474 T PL13773474 T PL 13773474T PL 13773474 T PL13773474 T PL 13773474T PL 2897978 T3 PL2897978 T3 PL 2897978T3
Authority
PL
Poland
Prior art keywords
methods
reduced immunogenicity
identifying antibodies
antibodies
identifying
Prior art date
Application number
PL13773474T
Other languages
English (en)
Inventor
Fiona A. Harding
Olivia Jennifer Razo
Original Assignee
Abbvie Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of PL2897978T3 publication Critical patent/PL2897978T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL13773474T 2012-09-19 2013-09-18 Sposoby identyfikacji przeciwciał o obniżonej immunogenności PL2897978T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261703170P 2012-09-19 2012-09-19

Publications (1)

Publication Number Publication Date
PL2897978T3 true PL2897978T3 (pl) 2017-08-31

Family

ID=49304336

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13773474T PL2897978T3 (pl) 2012-09-19 2013-09-18 Sposoby identyfikacji przeciwciał o obniżonej immunogenności

Country Status (27)

Country Link
US (1) US9279016B2 (pl)
EP (2) EP2897978B1 (pl)
JP (1) JP2015537190A (pl)
KR (1) KR20150056788A (pl)
CN (1) CN104704000A (pl)
AU (1) AU2013318147B2 (pl)
BR (1) BR112015005857A2 (pl)
CA (1) CA2885422A1 (pl)
CY (1) CY1118893T1 (pl)
DK (1) DK2897978T3 (pl)
ES (1) ES2621285T3 (pl)
HR (1) HRP20170937T1 (pl)
HU (1) HUE032569T2 (pl)
IL (1) IL237833A0 (pl)
IN (1) IN2015DN01967A (pl)
LT (1) LT2897978T (pl)
MX (1) MX2015003541A (pl)
NZ (1) NZ705606A (pl)
PL (1) PL2897978T3 (pl)
PT (1) PT2897978T (pl)
RS (1) RS56093B1 (pl)
RU (1) RU2648141C2 (pl)
SG (1) SG11201502094TA (pl)
SI (1) SI2897978T1 (pl)
SM (1) SMT201700255T1 (pl)
TW (1) TWI519646B (pl)
WO (1) WO2014047222A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ． ホフマン－ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
TW202039554A (zh) * 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
CN114401988A (zh) * 2019-07-09 2022-04-26 国家生物技术研究所公司 具有降低的免疫原性的抗体
WO2021064009A1 (en) 2019-09-30 2021-04-08 Scirhom Gmbh Protein binders to irhom2 epitopes
FR3104582A1 (fr) * 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Variants de l’adalimumab au potentiel immunogène réduit
CN113125714B (zh) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 一种人类免疫缺陷病毒抗体检测试剂盒及其应用
WO2021147642A1 (en) * 2020-01-20 2021-07-29 Bio-Thera Solutions, Ltd. Methods, models and systems related to antibody immunogenicity
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
MX2023010055A (es) 2021-03-01 2023-11-17 Scirhom Gmbh Anticuerpos humanizados contra irhom2.
US20240174744A1 (en) 2021-03-29 2024-05-30 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
CN119998325A (zh) 2022-08-08 2025-05-13 Atb治疗公司 抗CD79b的人源化抗体
WO2025180665A1 (en) 2024-02-28 2025-09-04 Evotec International Gmbh Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
WO2025242726A1 (en) 2024-05-21 2025-11-27 Onconick Ltd. Antibody binding to FGFR1 and conjugates comprising the same
WO2026087776A1 (en) * 2024-10-25 2026-04-30 Kyron.bio SAS Therapeutic molecules that bind tnf alpha

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
DE3687170T2 (de) 1985-01-25 1993-04-01 Kitasato Inst Antitumorale antibiotika und deren herstellung.
US5264357A (en) 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
WO2001023610A2 (en) 1999-09-29 2001-04-05 Solexa Ltd. Polynucleotide sequencing
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6897023B2 (en) 2000-09-27 2005-05-24 The Molecular Sciences Institute, Inc. Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6956114B2 (en) 2001-10-30 2005-10-18 '454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040115814A1 (en) 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI439284B (zh) * 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JP2009515878A (ja) 2005-11-12 2009-04-16 イーライ リリー アンド カンパニー 抗ｅｇｆｒ抗体
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
RU2595379C2 (ru) * 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
NZ602220A (en) * 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
BR112013002444A2 (pt) * 2010-08-13 2016-05-24 Roche Glycart Ag anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
CN103534268B (zh) * 2010-10-20 2016-05-18 牛津生物疗法有限公司 抗体

Also Published As

Publication number Publication date
TWI519646B (zh) 2016-02-01
AU2013318147B2 (en) 2018-01-04
LT2897978T (lt) 2017-06-12
SI2897978T1 (sl) 2017-05-31
EP2897978A2 (en) 2015-07-29
IL237833A0 (en) 2015-05-31
CA2885422A1 (en) 2014-03-27
PT2897978T (pt) 2017-05-22
RS56093B1 (sr) 2017-10-31
HRP20170937T1 (hr) 2017-11-03
RU2015111671A (ru) 2016-11-10
US9279016B2 (en) 2016-03-08
SG11201502094TA (en) 2015-04-29
BR112015005857A2 (pt) 2017-08-08
WO2014047222A2 (en) 2014-03-27
KR20150056788A (ko) 2015-05-27
CY1118893T1 (el) 2018-01-10
HK1211306A1 (en) 2016-05-20
NZ705606A (en) 2018-05-25
CN104704000A (zh) 2015-06-10
EP3211006A2 (en) 2017-08-30
JP2015537190A (ja) 2015-12-24
EP3211006A3 (en) 2017-11-08
ES2621285T3 (es) 2017-07-03
HUE032569T2 (en) 2017-09-28
US20140227251A1 (en) 2014-08-14
WO2014047222A3 (en) 2014-10-23
WO2014047222A9 (en) 2014-06-26
IN2015DN01967A (pl) 2015-08-14
TW201418469A (zh) 2014-05-16
RU2648141C2 (ru) 2018-03-22
MX2015003541A (es) 2015-10-26
SMT201700255T1 (it) 2017-07-18
EP2897978B1 (en) 2017-03-22
AU2013318147A1 (en) 2015-03-19
DK2897978T3 (en) 2017-05-15

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti–il–23p19 antibodies
IL237833A0 (en) Methods for identifying antibodies with reduced immunogenicity
ZA201407509B (en) Anti-fcrn antibodies
ZA201407897B (en) Protease-regulated antibodies
ZA201409358B (en) Anti-siglec- 15 antibodies
ZA201407316B (en) Anti-fgfr2 antibody
SG11201504765VA (en) Anti-h7cr antibodies
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
GB201220242D0 (en) Antibody
EP2852660A4 (en) PROCESS
EP2804876A4 (en) NEW ANTIBODIES
ZA201502210B (en) Methods for identifying hiv neutralizing antibodies
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations